Pazopanib.

Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat Rev Clin Oncol (2012) 1.37

Experimental approaches for the treatment of malignant gliomas. Pharmacol Ther (2010) 1.23

The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs (2011) 1.00

Pharmacologic uncoupling of angiogenesis and inflammation during initiation of pathological corneal neovascularization. J Biol Chem (2011) 0.90

Quantitative implementation of the endogenous molecular-cellular network hypothesis in hepatocellular carcinoma. Interface Focus (2014) 0.88

Gene and drug matrix for personalized cancer therapy. Nat Rev Drug Discov (2010) 0.86

A systems biology view of blood vessel growth and remodelling. J Cell Mol Med (2013) 0.86

Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway. Adv Urol (2012) 0.86

Tailoring tyrosine kinase inhibitors to fit the lung cancer genome. Transl Oncol (2011) 0.83

Recent updates of precision therapy for gastric cancer: Towards optimal tailored management. World J Gastroenterol (2016) 0.83

Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib. Clin Med Insights Oncol (2011) 0.82

A high-content EMT screen identifies multiple receptor tyrosine kinase inhibitors with activity on TGFβ receptor. Oncotarget (2016) 0.81

Targeting of proangiogenic signalling pathways in chronic inflammation. Nat Rev Rheumatol (2015) 0.81

Concise drug review: pazopanib and axitinib. Oncologist (2012) 0.81

DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo. Acta Pharmacol Sin (2016) 0.80

Novel strategies for treating relapsed/refractory urothelial carcinoma. Expert Rev Anticancer Ther (2010) 0.78

Advances in paediatric cancer treatment. Transl Pediatr (2014) 0.76

Structure-Activity Relationship of Indole-Tethered Pyrimidine Derivatives that Concurrently Inhibit Epidermal Growth Factor Receptor and Other Angiokinases. PLoS One (2015) 0.75

Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors. BMC Cancer (2013) 0.75

Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell Carcinoma. Oncol Rev (2016) 0.75

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58

Sunitinib in patients with metastatic renal cell carcinoma. JAMA (2006) 11.33

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther (2007) 2.91

Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem (2008) 1.66

Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin (2007) 1.62

Everolimus. Nat Rev Drug Discov (2009) 1.29

Anti-angiogenic targets in the treatment of advanced renal cell carcinoma. Curr Cancer Drug Targets (2008) 1.02

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39

Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 13.52

Sunitinib in patients with metastatic renal cell carcinoma. JAMA (2006) 11.33

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 6.86

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol (2008) 5.27

Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst (2007) 5.10

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol (2007) 4.40

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 3.65

Sunitinib efficacy against advanced renal cell carcinoma. J Urol (2007) 3.14

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol (2008) 3.00

Vorinostat. Nat Rev Drug Discov (2007) 2.83

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61

Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress. Circ Res (2006) 2.58

Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol (2006) 2.50

Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res (2010) 2.26

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer (2007) 2.25

Abatacept. Nat Rev Drug Discov (2006) 2.13

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer (2010) 2.10

Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol (2008) 2.00

Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med (2002) 1.95

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol (2008) 1.87

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res (2009) 1.79

Pegloticase. Nat Rev Drug Discov (2011) 1.76

Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer (2008) 1.70

F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol (2003) 1.70

Vemurafenib. Nat Rev Drug Discov (2011) 1.68

Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol (2007) 1.66

Tetrabenazine. Nat Rev Drug Discov (2009) 1.60

Eculizumab. Nat Rev Drug Discov (2007) 1.56

Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer (2006) 1.51

Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res (2003) 1.48

Therapy and outcome of small cell carcinoma of the kidney: report of two cases and a systematic review of the literature. Cancer (2003) 1.42

Dabigatran etexilate. Nat Rev Drug Discov (2008) 1.41

Sunitinib in advanced renal cell carcinoma: new treatment option? Curr Oncol Rep (2007) 1.39

Sipuleucel-T. Nat Rev Drug Discov (2010) 1.37

Tocilizumab. Nat Rev Drug Discov (2009) 1.36

Effect of decompressive craniectomy on intracranial pressure and cerebrospinal compensation following traumatic brain injury. J Neurosurg (2008) 1.35

Cabazitaxel. Nat Rev Drug Discov (2010) 1.34

Denosumab. Nat Rev Drug Discov (2010) 1.31

Cetuximab. Nat Rev Drug Discov (2004) 1.31

Panitumumab. Nat Rev Drug Discov (2006) 1.31

A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer (2009) 1.30

Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clin Cancer Res (2005) 1.30

Everolimus. Nat Rev Drug Discov (2009) 1.29

Liraglutide. Nat Rev Drug Discov (2010) 1.27

Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys (2004) 1.25

Dasatinib. Nat Rev Drug Discov (2006) 1.25

Azacitidine. Nat Rev Drug Discov (2005) 1.23

Enfuvirtide. Nat Rev Drug Discov (2003) 1.22

Daptomycin. Nat Rev Drug Discov (2003) 1.22

Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol (2010) 1.22

Erlotinib hydrochloride. Nat Rev Drug Discov (2005) 1.22

Asenapine. Nat Rev Drug Discov (2009) 1.21

Ipilimumab. Nat Rev Drug Discov (2011) 1.20

Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma. Clin Genitourin Cancer (2007) 1.19

Duloxetine hydrochloride. Nat Rev Drug Discov (2004) 1.17

Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin Cancer Res (2004) 1.16

Vismodegib. Nat Rev Drug Discov (2012) 1.16

Eribulin mesylate. Nat Rev Drug Discov (2011) 1.14

Oxaliplatin. Nat Rev Drug Discov (2004) 1.14

Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. J Urol (2007) 1.13

Tolvaptan. Nat Rev Drug Discov (2009) 1.13

Ivacaftor. Nat Rev Drug Discov (2012) 1.12

Febuxostat. Nat Rev Drug Discov (2009) 1.12

Golimumab. Nat Rev Drug Discov (2009) 1.11

Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel. Cancer (2006) 1.10

Lapatinib. Nat Rev Drug Discov (2007) 1.10

Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother (2007) 1.10

Lacosamide. Nat Rev Drug Discov (2008) 1.09

Bevacizumab. Nat Rev Drug Discov (2004) 1.09

Myeloid-derived suppressor cells: a novel therapeutic target. Curr Oncol Rep (2009) 1.09

Ranibizumab. Nat Rev Drug Discov (2006) 1.08

Sunitinib maleate. Nat Rev Drug Discov (2006) 1.07

Crizotinib. Nat Rev Drug Discov (2011) 1.05

The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma. Semin Oncol (2006) 1.05

Plerixafor. Nat Rev Drug Discov (2009) 1.04

Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study. Clin Genitourin Cancer (2009) 1.04

Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference. Cancer (2009) 1.04

Brentuximab vedotin. Nat Rev Drug Discov (2012) 1.04

Aflibercept. Nat Rev Drug Discov (2012) 1.04

Exenatide. Nat Rev Drug Discov (2005) 1.02